Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2013 / Cilt: 39 - Sayı: 1

Serum testosterone levels, testis volume, and the risk of prostate cancer: are these factors related?

Serum testosteron düzeyi, testis hacmi, ve prostat kanser riski: aralarında basit bir ilişki var mı?,

Pages
12–15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, monitoring serum testosterone levels for prostate cancer prediction does not appear to add an advantage over PSA screening.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Inconclusive results have been published in the literature regarding the relationship between free and total serum testosterone levels and prostate cancer.
📊
Key Findings & Data:Material and methods: Total and free serum testosterone levels and serum PSA levels were recorded for 102 consecutive patients.
💡
Conclusion & Impact:Therefore, monitoring serum testosterone levels for prostate cancer prediction does not appear to add an advantage over PSA screening.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Inconclusive results have been published in the literature regarding the relationship between free and total serum testosterone levels and prostate cancer. We investigated the relationship between total and free serum testosterone levels, testes volume, and prostate cancer in our patient population. Material and methods: Total and free serum testosterone levels and serum PSA levels were recorded for 102 consecutive patients. All of the patients underwent transrectal ultrasonography-guided prostate biopsy due to an abnormal digital rectal examination finding and/or a serum PSA level of >4.0 ng/mL. All of the transrectal and testis US examinations and prostate biopsies were performed by the same radiologist. The testis length, width, and height were measured from transverse and longitudinal gray scale images, and the testis volume was calculated. Results: Prostate cancer was detected in 32 of 102 patients (31.3%) who underwent prostate biopsy (prostate cancer group). The remaining patients had benign histopathological findings (prostate cancer-free group). The prostate cancer and benign histology groups were compared for age, total and free testosterone, PSA values, and testis volume. The patients with prostate cancer were found to have a higher mean age (p= 0.04). There were no significant differences in serum PSA levels, free or total testosterone levels, or testis volumes between the two groups (p>0.05). A binary logistic regression analysis showed that neither free nor total testosterone was a predictor of prostate cancer (p= 0.315 and p= 0.213, respectively). Only age was found to be a significant risk factor for the development of prostate cancer (p= 0.02). Conclusion: Our study failed to show a relationship between total or free serum testosterone levels, testis volume, and the risk of prostate cancer. Therefore, monitoring serum testosterone levels for prostate cancer prediction does not appear to add an advantage over PSA screening.

Özet

Amaç: Literatürde serum serbest ve total testosteron düzeyleri ve prostat kanseri arasındaki ilişki hakkında kesin olmayan sonuçlar bildirilmiştir. Biz kendi hasta grubumuzda total ve serbest serum testosteron düzey- leri, testis hacmi ve prostat kanseri arasındaki ilişkiyi araştırdık. Gereç ve yöntemler: Alt üriner sistem semptomları ile üroloji polikliniğine başvuran 102 hastada serum total ve serbest testosteron düzeyleri ve serum PSA değerleri kayıt edildi. Anormal rektal muayene bulgusu ve/veya >4.0ng/mL serum PSA düzeyi nedeni ile bütün hastalara transrektal ultrasonografi (US) rehber- liğinde prostat biyopsisi yapıldı. Bütün transrektal ve testis US incelemeleri ve biyopsileri aynı radyolog tarafından yapıldı. Testis uzunluğu, genişliği ve yüksekliği transvers ve longitudinal gri skala görüntülerde ölçüldü ve testis hacmi hesaplandı. Bulgular: Prostat biyopsisi yapılan 102 hastanın 32’sinde prostat kanseri saptandı (%31.3) (prostat kanseri grubu). Geri kalan hastalar benign histopatolojik bulgulara sahipti (prostat kansersiz grup). Prostat kanseri ve benign histoloji grupları yaş, total ve serbest testosteron, PSA değerleri ve testis hacmi açısından karşı- laştırıldı. Prostat kanseri olan hastaların ortalama yaşı daha büyük bulundu (p= 0.04). Serum PSA, serbest testosteron ya da total testosteron ve testis hacmi açısından iki grup arasında anlamlı fark yoktu (p>0.05). İkili lojistic regresyon analizi ne serbest ne de total testosteronun prostat kanseri için belirteç olmadığını göstermiştir (sırasıyla p= 0.315 ve 0.213). Sadece yaş prostat kanseri gelişimi açısından anlamlı bir faktör olarak bulunmuştur (p= 0.02). Sonuç: Çalışmamızda total, serbest serum testosteron düzeyleri, testis hacmi ve prostat kanseri riski arasın- da bir ilişki gösterilememiştir. Dolayısıyla prostat kanserini ön görmek için serum testosteron düzeylerine bakmak PSA taramasına katkı sağlıyor gibi görünmemektedir.

🔖

Cite This Article

HALİLOĞLU, A. H., GÖKCE, M. İ., ÖZCAN, C., BALTACI, S., YAMAN, Ö. (2013). Serum testosterone levels, testis volume, and the risk of prostate cancer: are these factors related?. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 39 - Sayı: 1, 12–15. https://ajindex.com/articles/328637

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, et al. Human Prostate Cancer Risk Factors. Cancer 2004
  2. [CrossRef] 2. Severi G, Morris HA, MacInnis RJ, et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006
  3. [CrossRef] 3. Chu LW, Reichardt JKV, Hsing AW. Androgens and the molecular epidemiology of prostate cancer. Curr Opin Endocrinol Diabetes Obes 2008
  4. [CrossRef] 4. Hsing AW, Chu LW, Stanczyk FZ. Androgen and prostate cancer: is the hypothesis dead? Cancer Epidemiol Biomarkers Prev 2008
  5. [CrossRef] 5. Morote J, Ramirez C, Gomez E, Planas J, Ranentos CX, Torres IM, et al. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness. BJU Int 2009
  6. [CrossRef] 6. Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ. Serum testosterone and the risk of prostate cancer: potential implications for testosterone theraphy. Cancer Epidemiol Biomarkers Prev 2005
  7. [CrossRef] 7. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002
  8. [CrossRef] 8. Stanworth RD, Jones TH. Testosterone fort he aging male
  9. current evidence and recommended practice. Clin Interv Aging 2008
  10. Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008
  11. [CrossRef] 10. Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Epidemiol Biomarkers Prev 2005
  12. [CrossRef] 11. Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, Schulman C. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol 2009
  13. [CrossRef] 12. Kristal AR, Schenk JM, Song Y, Arnold KB, Neuhouser ML, Goodman PJ, et al. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 2008
  14. [CrossRef] 13. Bahk JY, Jung JH, Jin LM, Min SK. Cut-off value of testes volume in yo